These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 15624359)

  • 1. [Tumor marker in primary lung cancer].
    Sugio K; Sugaya M; Hanagiri T; Yasumoto K
    J UOEH; 2004 Dec; 26(4):473-9. PubMed ID: 15624359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The diagnostic significance of single or combination lung cancer-related serum biomarkers in high risk lung cancer patients].
    Ni J; Guo Z; Zhang L
    Zhonghua Nei Ke Za Zhi; 2016 Jan; 55(1):25-30. PubMed ID: 26796649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
    Ma S; Shen L; Qian N; Chen K
    Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Combination of the Tumor Markers Suggests the Histological Diagnosis of Lung Cancer.
    Liu L; Teng J; Zhang L; Cong P; Yao Y; Sun G; Liu Z; Yu T; Liu M
    Biomed Res Int; 2017; 2017():2013989. PubMed ID: 28607926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Value and Clinical Significance of Combined Detection of Serum Markers CYFRA21-1, SCC Ag, NSE, CEA and ProGRP in Non-Small Cell Lung Carcinoma.
    Li Q; Sang S
    Clin Lab; 2020 Nov; 66(11):. PubMed ID: 33180443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation and therapeutic monitoring value of serum tumor markers in lung cancer.
    Wang L; Wang D; Zheng G; Yang Y; Du L; Dong Z; Zhang X; Wang C
    Int J Biol Markers; 2016 Feb; 31(1):e80-7. PubMed ID: 26560853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
    Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
    Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Value of tumor markers series of hydrothorax in differential diagnosis of pleural effusion].
    Liu YQ; Zhang HL; Gao WJ; Lan X; Yuan BJ; Zou JM
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2008 Jan; 26(1):34-8. PubMed ID: 18302890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A re-evaluation of squamous cell carcinoma antigen (SCC) as a serum marker for non-small cell lung cancer.
    Kagohashi K; Satoh H; Ishikawa H; Ohtsuka M; Sekizawa K
    Med Oncol; 2008; 25(2):187-9. PubMed ID: 17968682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
    Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
    Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
    Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tumor markers in lung cancer].
    Niho S; Shinkai T
    Gan To Kagaku Ryoho; 2001 Dec; 28(13):2089-93. PubMed ID: 11791391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Evaluation of Tumor Markers for Diagnosis in Patients with Non-small Cell Lung Cancer in China.
    Ma L; Xie XW; Wang HY; Ma LY; Wen ZG
    Asian Pac J Cancer Prev; 2015; 16(12):4891-4. PubMed ID: 26163610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic potential of protein serum biomarkers for distinguishing small and non-small cell lung cancer in patients with suspicious lung lesions.
    Sua LF; Serrano-Gomez SJ; Nuñez M; Amezquita-Dussan MA; Fernández-Trujillo L
    Biomarkers; 2024 Jul; 29(5):315-323. PubMed ID: 38804910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
    Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
    Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
    Jiang ZF; Wang M; Xu JL
    Life Sci; 2018 Feb; 194():1-6. PubMed ID: 29247745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective Study to Determine Diagnostic Utility of 6 Commonly Used Lung Cancer Biomarkers Among Han and Uygur Population in Xinjiang Uygur Autonomous Region of People's Republic of China.
    Yang-Chun F; Min F; Di Z; Yan-Chun H
    Medicine (Baltimore); 2016 May; 95(18):e3568. PubMed ID: 27149479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients.
    Yang DW; Zhang Y; Hong QY; Hu J; Li C; Pan BS; Wang Q; Ding FH; Ou JX; Liu FL; Zhang D; Zhou JB; Song YL; Bai CX
    Cancer; 2015 Sep; 121 Suppl 17():3113-21. PubMed ID: 26331818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer.
    Ando S; Suzuki M; Yamamoto N; Iida T; Kimura H
    Anticancer Res; 2004; 24(3b):1941-6. PubMed ID: 15274381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.